
    
      This is an observational, controlled, open-label and monocentric study. 60 patients are
      planned to be included.

      Knowledge are assessed three time by self-administered questionnaire:

      at baseline before the pharmacist's educational interview at three months apart at six months
      apart

      One primary end-point is defined:

      the changes from baseline to M3 and M6 in the patients' knowledge score about subcutaneous
      bDMARD management (self-administered questionnaire, Biosecure)

      As secondary end-points, the changes from baseline to M3 and M6 in patients' adherence,
      patients' satisfaction regarding the pharmacists' intervention and the effect of the
      interview on rate of patients treated by biosimilar are evaluated.
    
  